275 related articles for article (PubMed ID: 16249748)
1. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids.
Mourad M; Mourad G; Wallemacq P; Garrigue V; Van Bellingen C; Van Kerckhove V; De Meyer M; Malaise J; Eddour DC; Lison D; Squifflet JP; Haufroid V
Transplantation; 2005 Oct; 80(7):977-84. PubMed ID: 16249748
[TBL] [Abstract][Full Text] [Related]
2. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.
Haufroid V; Mourad M; Van Kerckhove V; Wawrzyniak J; De Meyer M; Eddour DC; Malaise J; Lison D; Squifflet JP; Wallemacq P
Pharmacogenetics; 2004 Mar; 14(3):147-54. PubMed ID: 15167702
[TBL] [Abstract][Full Text] [Related]
3. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
Yildirim E; Şahin G; Kaltuş Z; Çolak E
Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
[TBL] [Abstract][Full Text] [Related]
5. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.
Vannaprasaht S; Reungjui S; Supanya D; Sirivongs D; Pongskul C; Avihingsanon Y; Tassaneeyakul W
Clin Ther; 2013 Nov; 35(11):1762-9. PubMed ID: 24120259
[TBL] [Abstract][Full Text] [Related]
6. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
Rong G; Jing L; Deng-Qing L; Hong-Shan Z; Shai-Hong Z; Xin-Min N
Transplant Proc; 2010 Nov; 42(9):3455-8. PubMed ID: 21094796
[TBL] [Abstract][Full Text] [Related]
7. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
Tsuchiya N; Satoh S; Tada H; Li Z; Ohyama C; Sato K; Suzuki T; Habuchi T; Kato T
Transplantation; 2004 Oct; 78(8):1182-7. PubMed ID: 15502717
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
9. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients.
Miao LY; Huang CR; Hou JQ; Qian MY
Biopharm Drug Dispos; 2008 Jan; 29(1):1-5. PubMed ID: 17941052
[TBL] [Abstract][Full Text] [Related]
10. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
Cho JH; Yoon YD; Park JY; Song EJ; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.
Provenzani A; Notarbartolo M; Labbozzetta M; Poma P; Vizzini G; Salis P; Caccamo C; Bertani T; Palazzo U; Polidori P; Gridelli B; D'Alessandro N
Int J Mol Med; 2011 Dec; 28(6):1093-102. PubMed ID: 21922127
[TBL] [Abstract][Full Text] [Related]
13. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients.
Kuypers DR; de Jonge H; Naesens M; Vanrenterghem Y
Pharmacogenet Genomics; 2008 Oct; 18(10):861-8. PubMed ID: 18704002
[TBL] [Abstract][Full Text] [Related]
14. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients.
Chen Z; Cheng X; Zhang L; Tang L; Fang Y; Chen H; Zhang L; Shen A
Pharmacol Rep; 2021 Oct; 73(5):1418-1426. PubMed ID: 34089513
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients.
Wu P; Ni X; Wang M; Xu X; Luo G; Jiang Y
Ann Transplant; 2011; 16(1):54-60. PubMed ID: 21436775
[TBL] [Abstract][Full Text] [Related]
17. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
[TBL] [Abstract][Full Text] [Related]
18. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
[TBL] [Abstract][Full Text] [Related]
19. Impact of POR and CYP3A5 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in the Early Post-operative Period Following Kidney Transplantation.
Phupradit A; Vadcharavivad S; Ingsathit A; Kantachuvesiri S; Areepium N; Sra-Ium S; Auamnoy T; Sukasem C; Sumethkul V; Kitiyakara C
Ther Drug Monit; 2018 Oct; 40(5):549-557. PubMed ID: 29878980
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients.
Li D; Lu W; Zhu JY; Gao J; Lou YQ; Zhang GL
J Clin Pharm Ther; 2007 Oct; 32(5):505-15. PubMed ID: 17875118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]